RecombinantMIF, Human

Macrophage Migration Inhibitory Factor (MIF) is a pleiotropic cytokine, existing as a homotrimer in vivo. MIF was originally identified as a T cell derived factor responsible for the inhibition of macrophage migration. However, recently MIF has received much more attention because of its possible roles in angiogenesis and cancer development. MIF is over-expressed in various cancers, including pancreatic, breast, colon, brain, prostate, skin, and lung. The intratumoral expression of MIF is strongly correlated with angiogenic growth factor expression, such as the expression of Interleukin 8 (IL-8) and Vascular Endothelial Growth Factor (VEGF), and with risk of recurrence after resection. Recombinant human Macrophage Migration Inhibitory Factor (rhMIF) produced in E.coli is a single non-glycosylated polypeptide chain containing 115 amino acids. rhMIF has a molecular mass of 12.5 kDa analyzed by reducing SDS-PAGE and is obtained by proprietary chromatographic techniques at GenScript.

Product Specifications

Product Name Alternative

Macrophage Migration, Inhibitory Factor, GLIF, MMIF, GIF, Glycosylation-inhibiting factor

Source

Escherichia coli.

Endotoxin

< 0.2 EU/μg, determined by LAL method.

Purity

> 95% as analyzed by SDS-PAGE and HPLC.

Form

Lyophilized after extensive dialysis against PBS.

Molecular Weight

12.5 kDa, observed by reducing SDS-PAGE.

Storage Conditions

Lyophilized recombinant human Macrophage Migration Inhibitory Factor (rhMIF) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, rhMIF remains stable up to 2 weeks at 4°C or up to 3 months at -20°C.